Phio Pharmaceuticals Corp. (PHIO)

Phio Pharmaceuticals Corp.'s stock price has experienced significant fluctuations over the past six months, decreasing by 58.92%. In November 2025, the stock fell amid financing and clinical updates, but rose after positive trial results for PH-762 and the exercise of warrants for $13.4 million. In September 2025, biotech stocks, including Phio, rallied after hours due to trial progress and key updates. In August 2025, Phio reported a wider loss in its fiscal Q2. As of February 5, 2026, the share price was $0.86, representing a decline of 57.79% from February 6, 2025.

Phio Pharmaceuticals Corp. does not exhibit traditional demand seasonality for its products and services. Its revenue generation is primarily tied to research and development milestones, potential licensing agreements, and eventual drug approvals, rather than seasonal consumer demand. The company currently has no revenue from product sales.

Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on immuno-oncology therapeutics. Their core technology, INTASYL®, uses siRNA to enhance immune cells against tumors. Their lead program, PH-762, is in Phase 1b trials to reduce PD-1 expression in skin cancers, with early data showing some efficacy. PH-894 is in IND-enabling studies to silence BRD4, impacting both T cells and tumor cells. RXI-231 has shown promise in treating hyperpigmentation disorders by targeting tyrosinase.

Phio Pharmaceuticals Corp. is headquartered in Marlborough, Massachusetts, United States. Its operations and development of immuno-oncology therapeutics are primarily focused within the United States.

Phio Pharmaceuticals' brand reputation has been influenced by both positive developments and ongoing challenges. Positive events include the recognition of INTASYL PH-762 as the "Immunomodulatory Solution of the Year" and positive early safety data from PH-762 trials. Challenges include risks associated with clinical trials, funding, potential dilutive capital raises, concerns about commercial success, and the substantial decline in stock price.

Phio Pharmaceuticals Corp. has 18 institutional owners and shareholders, holding a total of 258,088 shares. Major institutional owners include Vanguard Group Inc., Geode Capital Management, Llc, and others. Robert Bitterman (Chairman, President & CEO) holds a significant percentage of shares. Insider sentiment for PHIO is positive, with 10 different insiders buying over the last year.